Welcome!
To use the personalized features of this site, please log in or register.
If you have forgotten your username or password, we can help.
|
 |
Papillary Microcarcinoma
| |
 |
Shiro Noguchi1  , Hiroto Yamashita1, Shinya Uchino1 and Shin Watanabe1
| (1) |
Noguchi Thyroid Clinic and Hospital Foundation, Beppu, Japan |
Published online: 11 February 2008
Abstract
Background Papillary microcarcinoma (PMC) is increasing in incidence because of diagnosis by ultrasound-guided fine-needle aspiration
cytology.
Methods Between January 1966 and December 1995, we treated 6019 patients with papillary cancer; among them, 2070 patients with PMC
were studied.
Results PMC is essentially very similar to papillary cancer that is 11 mm or larger and has a very good prognosis. Smaller tumors
and younger patients have a better prognosis. Among PMC, larger tumors (6–10 mm) recur in 14% at 35 years compared with 3.3%
in patients with smaller tumors. Patients older than 55 years have recurrence in 40% at 30 years, with a worse prognosis than
younger patients who have a recurrence rate of less than 10%. Extracapsular invasion by the primary tumor also has a higher
recurrence rate. The majority of recurrences are in the neck. Therefore, annual ultrasound of the neck is effective for recurrence
surveillance.
Conclusion Papillary microcarcinoma is similar to larger papillary carcinomas with tumor characteristics and age-based recurrence rate
that extends for many years, justifying long surveillance after surgery.
References
| 1. |
Ito Y, Uruno T, Nakano K et al (2003) An observation trial without surgical treatment in patients with papillary microcarcinoma
of the thyroid. Thyroid 13:381–387
|
| |
| 2. |
Kucuk NO, Tari P, Tokmak E et al (2007) Treatment for microcarcinoma of the thyroid—clinical experience. Clin Nucl Med 32:279–281
|
| |
| 3. |
Pelizzo MR, Boschin IM, Toniato A et al (2006) Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and
outcome in 403 patients. Eur J Surg Oncol 32:1144–1148
|
| |
| 4. |
Fukunaga FH, Yatani R (1975) Geographic pathology of occult thyroid carcinomas. Cancer 36:1095–1099
|
| |
| 5. |
Grant S, Luttrell B, Reeve T et al (1984) Thyroglobulin may be undetectable in the serum of patients with metastatic disease
secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma. Cancer 54:1625–1628
|
| |
| 6. |
Noguchi S, Yamashita H, Murakami N et al (1996) Small carcinomas of the thyroid. A long-term follow-up of 867 patients. Arch
Surg 131:187–191
|
| |
| 7. |
Cady B, Rossi R, Silverman M et al (1985) Further evidence of the validity of risk group definition in differentiated thyroid
carcinoma. Surgery 98:1171–1178
|
| |
| 8. |
Chow SM, Law SC, Chan JK et al (2003) Papillary microcarcinoma of the thyroid: Prognostic significance of lymph node metastasis
and multifocality. Cancer 98:31–40
|
| |
| 9. |
Vini L, Hyer S, Pratt B et al (1999) Good prognosis in thyroid cancer found incidentally at surgery for thyrotoxicosis. Postgrad
Med J 75:169–170
|
| |
| 10. |
Belfiore A, Garofalo MR, Giuffrida D et al (1990) Increased aggressiveness of thyroid cancer in patients with Graves’ disease.
J Clin Endocrinol Metab 70:830–835
|
| |
| 11. |
Hales IB, McElduff A, Crummer P et al (1992) Does Graves’ disease or thyrotoxicosis affect the prognosis of thyroid cancer?
J Clin Endocrinol Metab 75:886–889
|
| |
| 12. |
Kasuga Y, Sugenoya A, Kobayashi S et al (1993) The outcome of patients with thyroid carcinoma and Graves’ disease. Surg Today
23:9–12
|
| |
| 13. |
Rassael H, Thompson LD, Heffess CS (1998) A rationale for conservative management of microscopic papillary carcinoma of the
thyroid gland: a clinicopathologic correlation of 90 cases. Eur Arch Otorhinolaryngol 255:462–467
|
| |
| 14. |
Salvadori B, Del Bo R, Pilotti S et al (1993) “Occult” papillary carcinoma of the thyroid: a questionable entity. Eur J Cancer
29A:1817–1820
|
| |
| 15. |
Singh B, Shaha AR, Trivedi H et al (1999) Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact on presentation,
management, and outcome. Surgery 126:1070–1076; discussion 1076–1077
|
| |
| 16. |
Derwahl M, Broecker M, Kraiem Z (1999) Clinical review 101: Thyrotropin may not be the dominant growth factor in benign and
malignant thyroid tumors. J Clin Endocrinol Metab 84:829–834
|
| |
| 17. |
Pelizzo MR, Boschin IM, Toniato A et al (2004) Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma
(PTMC): a mono-institutional 12-year experience. Nucl Med Commun 25:547–552
|
| |
| 18. |
Sakorafas GH, Stafyla V, Kolettis T et al (2007) Microscopic papillary thyroid cancer as an incidental finding in patients
treated surgically for presumably benign thyroid disease. J Postgrad Med 53:23–26
|
| |
| 19. |
Sanders LE, Rossi RL (1995) Occult well differentiated thyroid carcinoma presenting as cervical node disease. World J Surg
19:642–646; discussion 646–647
|
| |
| 20. |
Furlan JC, Bedard Y, Rosen IB (2001) Biologic basis for the treatment of microscopic, occult well-differentiated thyroid cancer.
Surgery 130:1050–1054
|
| |
| 21. |
Baudin E, Travagli JP, Ropers J et al (1998) Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience.
Cancer 83:553–559
|
| |
| 22. |
Rodriguez JM, Moreno A, Parrila P et al (1997) Papillary thyroid microcarcinoma: clinical study and prognosis. Eur J Surg
163:255–259
|
| |
|
|
|
|
|
|